Literature DB >> 18329386

Identification of operator sites within the upstream region of the putative mce2R gene from mycobacteria.

Vaibhav Vindal1, Enjapoori Ashwantha Kumar, Akash Ranjan.   

Abstract

Mycobacterium tuberculosis harbors four mce operons. Among them, mce2 operon is preceded by a FadR-like regulator mce2R (Rv0586). Here, we report the operator sites of the mce2R and its orthologs in other sequenced mycobacteria and non-mycobacterial species Nocardia farciana. All the identified DNA motifs illustrate the FadR subfamily specific nucleotide preference. Moreover, these motifs from the upstream region share sequence conservation, which is in agreement with the similarity of their DNA binding domain. Using electrophoretic mobility shift assay, we demonstrate that the predicted DNA motifs specifically interact with the recombinant Mce2R-Rv0586. Our present study has implications in the understanding of cis-regulatory elements and the auto-regulatory nature of the FadR subfamily of regulators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329386     DOI: 10.1016/j.febslet.2008.02.074

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Functional analysis of an intergenic non-coding sequence within mce1 operon of M.tuberculosis.

Authors:  Monika Joon; Shipra Bhatia; Rashmi Pasricha; Mridula Bose; Vani Brahmachari
Journal:  BMC Microbiol       Date:  2010-04-27       Impact factor: 3.605

2.  Genetic heterogeneity revealed by sequence analysis of Mycobacterium tuberculosis isolates from extra-pulmonary tuberculosis patients.

Authors:  Sarbashis Das; Tanmoy Roychowdhury; Parameet Kumar; Anil Kumar; Priya Kalra; Jitendra Singh; Sarman Singh; H K Prasad; Alok Bhattacharya
Journal:  BMC Genomics       Date:  2013-06-17       Impact factor: 3.969

3.  MycoRRdb: a database of computationally identified regulatory regions within intergenic sequences in mycobacterial genomes.

Authors:  Mohit Midha; Nirmal K Prasad; Vaibhav Vindal
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.